Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab in Ovarian Cancer
NCT01146795Phase 2Completed
- Start
- May 2010
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC). Primary endpoint: Number of Protocol Defined Adverse Events. Started May 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT01146795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01146795.